Applications of RWE in Precision Oncology Research

Wednesday, June 15 | 5.30 pm - 7.30 pm | Boston, MA | In-Person Event Only

Please Note: This event is taking place in-person only, and online attendance will not be available.

This Guardant Health Engager is an exclusive, limited-attendance event that will review and discuss the latest trends in the use of breast oncology trials and RWE in precision oncology research covering R&D, clinical trials, and post-market applications.

Join us to delve into the value of incorporating patient and HCP-level data in clinical and commercial strategies, and discover how to optimize clinical trial design and commercial effectiveness using RWE.

This is a forward-looking discussion specifically designed for highlevel executives from BioPharma based in the US looking to accelerate clinical trials, extract value from cutting-edge innovation, and expand therapeutic access for cancer patients.

YOUR EXPERT SPEAKERS

Aditya Bardia

Assistant Professor & Attending Physician

Massachusetts General Hospital Cancer Center

Asieh Golozar

VP, Global Head of Data Science, Odysseus Data Services & Professor of the Practice & Director of Clinical Research, OHDSI Center, Northeastern University

Craig Eagle

Chief Medical Officer

Guardant Health

John Strickler

Associate Professor of Medicine

Duke University

Mark Stewart

Vice President of Science Policy

Friends of Cancer Research

Please Note: This event is taking place in-person only, and online attendance will not be available.

This event is reserved for decision makers and senior representatives in the biopharma community with therapies in their pipeline. By registering online, you are submitting your interest in this exclusive networking meeting, and a colleague will be in touch upon registering to confirm or decline your place based on the mentioned criteria.

Having trouble registering? Email: info@hansonwade.com

*Attendance is subject to final approval from the event organizers

VENUE & AGENDA DETAILS

The Applications of RWE in Precision Oncology Research Event will be held at:

Yvonnes Boston

2 Winter Pl, Boston, MA 02108.  Room: The Gallery

Check Out Their Website Here

Applications of RWE in Precision Oncology Research

Wednesday, June 15 | 5.30pm – 7.30pm | Boston, MA

5:30 pm Registration & Welcome Reception

6:00 pm Opening Remarks & Introduction

6:10 pm Panel Discussion: Applications of RWE in Precision Oncology Research

  • Craig Eagle Chief Medical Officer, Guardant Health
  • Aditya Bardia Assistant Professor & Attending Physician, Massachusetts General Hospital Cancer Center
  • Mark Stewart Vice President of Science Policy, Friends of Cancer Research
  • John Strickler Associate Professor of Medicine, Duke University
  • Asieh Golozar VP, Global Head of Data Science, Odysseus Data Services & Professor of the Practice & Director of Clinical Research, OHDSI Center, Northeastern University ,

Synopsis

• Discuss the value of incorporating patient and HCP-level data in clinical and commercial strategies
• Hear the latest trends in breast oncology trials and the use of RWE in precision oncology research
• Maximize launch campaigns by leveraging patient and HCP-level data

6:50 pm Networking & Drinks

Synopsis

This is an informal and exclusive networking opportunity for you to engage with Guardant Health over some appetizers and a few drinks.

7:30 pm End of Guardant Health Engager

ABOUT OUR HOST

Guardant-Health-corporate-logo-1

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield test, aims to address the needs of individuals eligible for cancer screening.